Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury

Neurobiology of Disease

Volumn 32, Issue 2, 2008, Pages 319-327

  Vučković, Marta G ^a,b   Wood, Ruth I ^a   Holschneider, Daniel P ^a,c   Abernathy, Avery ^b   Togasaki, Daniel M ^b   Smith, Alexandra ^b   Petzinger, Giselle M ^b   Jakowec, Michael W ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Affective behavior; Anxiety; Conditioned fear; Depression; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; SEROTONIN;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ASSOCIATIVE MEMORY; CONDITIONING; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; EXTRAPYRAMIDAL SYNDROME; FEAR; FOOD PREFERENCE; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MENTAL INSTABILITY; MOOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; SEROTONIN BRAIN LEVEL; SOCIAL BEHAVIOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADAPTATION, PHYSIOLOGICAL; ANALYSIS OF VARIANCE; ANIMALS; BASAL GANGLIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOPAMINE; EXPLORATORY BEHAVIOR; FEAR; FOOD PRESERVATION; HINDLIMB SUSPENSION; MALE; MEMORY; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; SEROTONIN; SOCIAL BEHAVIOR; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 53749092558     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.07.015     Document Type: Article

References (80)

1. Agid Y., and Blin J. Nerve cell death in degenerative diseases of the central nervous system: clinical aspects. Ciba Found Symp. 126 (1987) 3-29
2. Agid Y., Cervera P., Hirsch E., Javoy-Agid F., Lehericy S., Raisman R., and Ruberg M. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov. Disord. 4 Suppl 1 (1989) S126-S144
3. Alcaro A., Huber R., and Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res. Rev. 56 (2007) 283-321
4. Avale M.E., Nemirovsky S.I., Raisman-Vozari R., and Rubinstein M. Elevated serotonin is involved in hyperactivity but not in the paradoxical effect of amphetamine in mice neonatally lesioned with 6-hydroxydopamine. J. Neurosci. Res. 78 (2004) 289-296
5. Berger-Sweeney J., Stearns N.A., Frick K.M., Beard B., and Baxter M.G. Cholinergic basal forebrain is critical for social transmission of food preferences. Hippocampus 10 (2000) 729-738
6. Berger T.W., Kaul S., Stricker E.M., and Zigmond M.J. Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res. 336 (1985) 354-358
7. Boissier J.R., and Simon P. The exploration reaction in the mouse. Preliminary note. Therapie 17 (1962) 1225-1232
8. Bowers D., Miller K., Mikos A., Kirsch-Darrow L., Springer U., Fernandez H., Foote K., and Okun M. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli. Brain 129 (2006) 3356-3365
9. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., Morgese M.G., Popoli P., and Alleva E. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. (2008)
10. Brown M.R., Rivier C., and Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 114 (1984) 1546-1549
11. Crawley J.N. Exploratory behavior models of anxiety in mice. Neurosci. Biobehav. Rev. 9 (1985) 37-44
12. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 57 (2008) 809-818
13. Cummings J.L. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149 (1992) 443-454
14. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
15. Davis M., and Whalen P.J. The amygdala: vigilance and emotion. Mol. Psychiatry 6 (2001) 13-34
16. Dluzen D.E., and Kreutzberg J.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res. 609 (1993) 98-102
17. do-Rego J.C., Viana A.F., Le Maitre E., Deniel A., Rates S.M., Leroux-Nicollet I., and Costentin J. Comparisons between anxiety tests for selection of anxious and non anxious mice. Behav. Brain Res. 169 (2006) 282-288
18. Falls W.A., Miserendino M.J., and Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J. Neurosci. 12 (1992) 854-863
19. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M., and Del Rio J. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 (2001) 288-296
20. Gotham A.M., Brown R.G., and Marsden C.D. Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49 (1986) 381-389
21. Greba Q., Gifkins A., and Kokkinidis L. Inhibition of amygdaloid dopamine D2 receptors impairs emotional learning measured with fear-potentiated startle. Brain Res. 899 (2001) 218-226
22. Greba Q., and Kokkinidis L. Peripheral and intraamygdalar administration of the dopamine D1 receptor antagonist SCH 23390 blocks fear-potentiated startle but not shock reactivity or the shock sensitization of acoustic startle. Behav. Neurosci. 114 (2000) 262-272
23. Guarraci F.A., Frohardt R.J., Young S.L., and Kapp B.S. A functional role for dopamine transmission in the amygdala during conditioned fear. Ann. N. Y. Acad. Sci. 877 (1999) 732-736
24. Gundersen H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 247 (1987) 229-263
25. Helmstetter F.J. Contribution of the amygdala to learning and performance of conditional fear. Physiol. Behav. 51 (1992) 1271-1276
26. Holmes A., Wrenn C.C., Harris A.P., Thayer K.E., and Crawley J.N. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 1 (2002) 55-69
27. Hornykiewicz O. The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease. Wien. Klin. Wochenschr. 75 (1963) 309-312
28. Irwin I., Finnegan K.T., Delanney L.E., Di Monte D., and Langston J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res. 572 (1992) 224-231
29. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegen 4 (1995) 257-269
30. Jakowec M.W., Donaldson D.M., Barba J., and Petzinger G.M. Postnatal expression of alpha-synuclein protein in the rodent substantia nigra and striatum. Dev. Neurosci. 23 (2001) 91-99
31. Jakowec M.W., Nixon K., Hogg E., McNeill T., and Petzinger G.M. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J. Neurosci. Res. 76 (2004) 539-550
32. Jones M.D., and Lucki I. Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. Neuropsychopharmacology 30 (2005) 1039-1047
33. Kilpatrick I.C., Jones M.W., and Phillipson O.T. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46 (1986) 1865-1876
34. Kogan J.H., Frankland P.W., Blendy J.A., Coblentz J., Marowitz Z., Schutz G., and Silva A.J. Spaced training induces normal long-term memory in CREB mutant mice. Curr. Biol. 7 (1997) 1-11
35. Ledgerwood L., Richardson R., and Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav. Neurosci. 117 (2003) 341-349
36. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 23 (2000) 155-184
37. Lira A., Zhou M., Castanon N., Ansorge M.S., Gordon J.A., Francis J.H., Bradley-Moore M., Lira J., Underwood M.D., Arango V., Kung H.F., Hofer M.A., Hen R., and Gingrich J.A. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54 (2003) 960-971
38. Liu X., Peprah D., and Gershenfeld H.K. Tail-suspension induced hyperthermia: a new measure of stress reactivity. J. Psychiatr. Res. 37 (2003) 249-259
39. Mann D.M., and Yates P.O. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum. Neurobiol. 5 (1986) 147-158
40. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21 (1999) 99S-105S
41. Maren S., and Quirk G.J. Neuronal signalling of fear memory. Nat. Rev. Neurosci. 5 (2004) 844-852
42. Marowsky A., Yanagawa Y., Obata K., and Vogt K.E. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron 48 (2005) 1025-1037
43. Mayorga A.J., Dalvi A., Page M.E., Zimov-Levinson S., Hen R., and Lucki I. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298 (2001) 1101-1107
44. McCance-Katz E.F., Marek K.L., and Price L.H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42 (1992) 1813-1814
45. Meredith G.E., and Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21 (2006) 1595-1606
46. Meredith G.E., Sonsalla P.K., and Chesselet M.F. Animal models of Parkinson's disease progression. Acta Neuropathol. 115 (2008) 385-398
47. Nader K., and LeDoux J. The dopaminergic modulation of fear: quinpirole impairs the recall of emotional memories in rats. Behav. Neurosci. 113 (1999) 152-165
48. Passe D.H., and Walker J.C. Odor psychophysics in vertebrates. Neurosci. Biobehav. Rev. 9 (1985) 431-467
49. Paulus W., and Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50 (1991) 743-755
50. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates (2001), Academic Press, San Diego
51. Perez-Otano I., Herrero M.T., Oset C., De Ceballos M.L., Luquin M.R., Obeso J.A., and Del Rio J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res. 567 (1991) 127-132
52. Petzinger G.M., Fisher B., Hogg E., Abernathy A., Arevalo P., Nixon K., and Jakowec M.W. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. J. Neurosci. Res. 83 (2006) 332-347
53. Petzinger G.M., Quik M., Ivashina E., Jakowec M.W., Jakubiak M., Di Monte D., and Langston J.W. Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate. Mov. Disord. 16 (2001) 202-207
54. Petzinger G.M., Walsh J.P., Akopian G., Hogg E., Abernathy A., Arevalo P., Turnquist P., Vuckovic M., Fisher B.E., Togasaki D.M., and Jakowec M.W. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27 (2007) 5291-5300
55. Pifl C., Schingnitz G., and Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44 (1991) 591-605
56. Pillon B., Dubois B., Bonnet A.M., Esteguy M., Guimaraes J., Vigouret J.M., Lhermitte F., and Agid Y. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 39 (1989) 762-768
57. Pillon B., Dubois B., Cusimano G., Bonnet A.M., Lhermitte F., and Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?. J. Neurol. Neurosurg. Psychiatry 52 (1989) 201-206
58. Ponnusamy R., Nissim H.A., and Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn. Mem. 12 (2005) 399-406
59. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
60. Pugh C.R., Tremblay D., Fleshner M., and Rudy J.W. A selective role for corticosterone in contextual-fear conditioning. Behav. Neurosci. 111 (1997) 503-511
61. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 Suppl 1 (2000) 2-19
62. Ross R.S., McGaughy J., and Eichenbaum H. Acetylcholine in the orbitofrontal cortex is necessary for the acquisition of a socially transmitted food preference. Learn. Mem. 12 (2005) 302-306
63. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., and Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14 (2003) 218-228
64. Rozas G., Lopez-Martin E., Guerra M.J., and Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods 83 (1998) 165-175
65. Russ H., Mihatsch W., Gerlach M., Riederer P., and Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?. Neurosci. Lett. 123 (1991) 115-118
66. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275 (1983) 321-328
67. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 30 (2000) 171-182
68. Slaughter J.R., Slaughter K.A., Nichols D., Holmes S.E., and Martens M.P. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13 (2001) 187-196
69. Snyder A.M., Zigmond M.J., and Lund R.D. Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J. Comp. Neurol. 245 (1986) 274-281
70. Stachowiak M.K., Stricker E.M., Jacoby J.H., and Zigmond M.J. Increased tryptophan hydroxylase activity in serotonergic nerve terminals spared by 5,7-dihydroxytryptamine. Biochem. Pharmacol. 35 (1986) 1241-1248
71. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85 (1985) 367-370
72. Strekalova T., Spanagel R., Bartsch D., Henn F.A., and Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 29 (2004) 2007-2017
73. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 178 (2002) 80-90
74. Tillerson J.L., and Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods 123 (2003) 189-200
75. Walker D.L., Ressler K.J., Lu K.T., and Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 22 (2002) 2343-2351
76. Walsh K., and Bennett G. Parkinson's disease and anxiety. Postgrad. Med. J. 77 (2001) 89-93
77. Wood S.J., and Toth M. Molecular pathways of anxiety revealed by knockout mice. Mol. Neurobiol. 23 (2001) 101-119
78. Wrenn C.C., Harris A.P., Saavedra M.C., and Crawley J.N. Social transmission of food preference in mice: methodology and application to galanin-overexpressing transgenic mice. Behav. Neurosci. 117 (2003) 21-31
79. Wright J.W., and Harding J.W. Recovery of olfactory function after bilateral bulbectomy. Science 216 (1982) 322-324
80. Yamazoe I., Takeuchi Y., Matsushita H., Kawano H., and Sawada T. Serotonergic heterotypic sprouting in the unilaterally dopamine-depleted mouse neostriatum. Dev. Neurosci. 23 (2001) 78-83